KMT2AR
Clinical trials for KMT2AR explained in plain language.
Never miss a new study
Get alerted when new KMT2AR trials appear
Sign up with your email to follow new studies for KMT2AR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for Hard-to-Treat leukemia: drug combo trial launches
Disease control Recruiting nowThis early-stage study tests a new drug called ziftomenib combined with standard treatments for people with a type of acute myeloid leukemia (AML) that has come back or not responded to therapy. The main goal is to check safety and find the best dose. About 171 adults with specif…
Matched conditions: KMT2AR
Phase: PHASE1 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated May 26, 2026 05:51 UTC
-
New combo therapy targets tough leukemia gene mutations
Disease control Recruiting nowThis early-stage study tests an experimental drug called ziftomenib added to usual treatments for acute myeloid leukemia (AML) in people with specific gene changes (NPM1 mutation or KMT2A rearrangement). About 420 adults with newly diagnosed or returning AML will receive ziftomen…
Matched conditions: KMT2AR
Phase: PHASE1 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated May 22, 2026 14:01 UTC